Poor Pathologist Agreement for Low-Grade Dysplasia in Barrett's

Share this content:
Poor Pathologist Agreement for Low-Grade Dysplasia in Barrett's
Poor Pathologist Agreement for Low-Grade Dysplasia in Barrett's

MONDAY, Feb. 6, 2017 (HealthDay News) -- There is poor agreement between pathologists in diagnosis of low-grade dysplasia (LGD) in patients with Barrett's esophagus (BE), according to a study published in the February issue of Gastroenterology.

Prashanth Vennalaganti, M.D., from the Veterans Affairs Medical Center in Kansas City, Mo., and colleagues discussed the diagnostic criteria for LGD and then reviewed 72 slides from patients with BE identified from seven pathologists (four from the United States and three from Europe). Slides included 23 samples of non-dysplastic BE, 22 LGD samples, and 34 high-grade dysplasia samples.

The researchers found that the overall κ value was 0.43 for diagnosis. The κ values were 0.22 for non-dysplastic BE, 0.11 for LGD, and 0.43 for high-grade dysplasia when categorized based on degree of dysplasia. The inter-observer agreement was considerable among the U.S. and European pathologists (κ, 0.63 and 0.80, respectively) when all pathologists made a diagnosis with high confidence. For all diagnoses, the κ values were higher for those made by European versus U.S. pathologists.

"In an analysis of criteria used in histopathologic diagnosis of LGD, we did not observe improvement in level of agreement among experienced pathologists, even after accounting for inflammation," the authors write. "The level of inter-observer agreement increased with level of pathologist confidence."

One author disclosed financial ties to the biopharmaceutical industry.

Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Bavencio for Merkel Cell Carcinoma

FDA Approves Bavencio for Merkel Cell Carcinoma

Drug targets the PD-1/PD-L1 pathway; first sanctioned treatment in the United States

Heterogeneous Association for Alcohol, CVD Presentation

Heterogeneous Association for Alcohol, CVD Presentation

Non-drinking linked to increased risks of unstable angina, MI, heart failure, ischemic stroke, PAD, AAA

Mobile App Cuts In-Person Visits After Breast Reconstruction

Mobile App Cuts In-Person Visits After Breast Reconstruction

Number of visits down, increase in e-mails to doctors for ambulatory patients undergoing breast recon

is free, fast, and customized just for you!

Already a member?

Sign In Now »